Circuit Clinical partners with the University at Buffalo’s genomics and biorepository program to add personalized medicine capabilities to its service offering lineup.
Bringing together the food industry’s know-how and pharma’s manufacturing expertise, the new joint venture from Lonza and Chr. Hansen is positioned to pioneer the live biotherapeutic products space – addressing medical needs not met with ‘conventional’...
Catalent Pharma invests $5m in drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
Metrion Biosciences looks to partner and move its lead candidate into clinical trials later this year fueled by a funding round which will also see its drug discovery services expand throughout 2019.
Horizon Discovery is working with St George’s University Hospital and EMQN to develop reference material for non-invasive prenatal testing, which is being increasingly adopted in the UK and abroad.
Sinclair Research and Turner Scientific sign an exclusive partnership through which the CROs will offer ototoxicity testing services – and improve regulatory guidance regarding the ears to protect patients, says company executive.
Cell One Partners formally launches its consulting services and aims to be a long-term partner to its clients, supporting the development of cell and gene therapies – a market which raised more than $13.3bn in 2018.
The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.
Lundbeck extends its research collaboration with the drug discovery services provider Enamine to help “intensify its search for quality lead compounds.”
LabCorp’s collaboration with Mission Bio will use single cell-sequencing technology to understand the genetics of rare cell populations, which could be key to making clinical trials successful, says CEO.
Clinical trials in the UK are reportedly declining as the country grapples with Brexit – a change which could make access to preclinical and bioanalytical research materials, including NHPs, problematic, says QPS.
Evotec AG is partnering with the Mark Foundation for Cancer Research to discover and develop first-in-class therapeutics in oncology using its new drug discovery platform.
